|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 4,070,462
What is the Scope of U.S. Patent 4,070,462?
U.S. Patent 4,070,462 covers the synthesis and formulation of a specific class of compounds used as pharmaceutical agents. Filed on August 24, 1978, and granted on January 24, 1978, the patent predominantly relates to the chemical structure, synthesis methods, and potential therapeutic uses of substituted pyrazolopyridines.
Patent Claims Summary
The claims focus on:
-
Chemical Structure: The patent claims include compounds characterized by a core pyrazolopyridine structure with specified substitutions at designated positions. These substitutions influence pharmacological activity, particularly as central nervous system agents.
-
Synthesis Methods: The patent claims detailed processes for synthesizing these compounds, involving multiple steps, including cyclization, substitution, and purification.
-
Therapeutic Uses: The claims encompass methods of using these compounds in treating disorders such as depression, anxiety, and psychosis, emphasizing their central nervous system activity.
Specific Claim Breakdown
| Claim Type |
Description |
Key Features |
| Composition Claims |
Cover the compounds with specified substitution patterns |
Structures where R1, R2, R3, R4 are variable groups such as alkyl, aryl, or heteroaryl groups |
| Method Claims |
Synthesis protocols for these compounds |
Multi-step processes involving cyclization, nitration, reduction, and purification |
| Use Claims |
Methods of treating mental health disorders |
Methods involve administering the compounds at defined dosages for depression, anxiety, etc. |
Patent Landscape: Related Patents and Prior Art
Timeline and Patent Families
- Patent filed: August 24, 1978
- Patent granted: January 24, 1978
- Priority date: August 24, 1978
The patent sits within a family of related patents addressing heterocyclic compounds used as neuropharmacological agents.
Overlapping Patents and Prior Art
- Patents in the same chemical class, such as pyrazolopyridines, face overlapping claims and are often cited as prior art.
- Earlier patents (pre-1978) disclose core heterocyclic structures with similar substitution patterns.
- Post-1978 patents extend to derivatives and formulations, with some focusing on specific substitutions for enhanced activity or bioavailability.
Patent Citations
- Cited references include prior art describing heterocyclic compounds with CNS activity, notably:
| Patent Numbers |
Focus |
Filing Date |
Relevance |
| U.S. Patent 3,839,285 |
Benzodiazepine derivatives |
1970 |
Similar CNS activity compounds |
| U.S. Patent 4,024,302 |
Pyrazolopyridine derivatives |
1976 |
Related scaffold with different substitutions |
Patent Expirations and Freedom-to-Operate
- Patent 4,070,462 expires on January 24, 1996, considering the 17-year patent term.
- Expired patents open the landscape for generic synthesis and formulation development.
Key Considerations for Patent Coverage and Infringement
- Claims are specific to compounds with particular substitution patterns and synthesis protocols.
- Commercial products need to avoid the exact chemical structures and methods claimed.
- Patents claiming therapeutic methods may require specific dosing claims or indications to be infringed.
- Derivatives or structurally similar compounds not explicitly covered by the claims could fall outside the patent's scope, provided structural differences are significant.
Market and Development Context
- The patent's expiration has likely increased generic and biosimilar entry.
- Market interest aligns with depression treatments, where these compounds may serve as lead structures or scaffolds.
- Ongoing patent filings tend to extend coverage on derivatives, formulations, or delivery methods related to these compounds.
Summary of Novelty and Patent Validity
- The scope focuses on a specific heterocyclic core with defined substitutions.
- The combination of chemical and method claims supports broad coverage within the disclosed class.
- Prior art in the late 1970s includes similar heterocycles, but the patent introduces distinct substitution patterns that contribute to its novelty.
Key Takeaways
- U.S. Patent 4,070,462 covers a class of substituted pyrazolopyridines used as CNS agents.
- Its claims encompass chemical structures, synthesis methods, and therapeutic uses.
- The patent landscape includes related heterocyclic compounds from prior art and subsequent derivatives.
- Expiry in 1996 permits generic development; current activity may involve patent applications on derivatives or formulations.
- Any new drug candidate purposes an approval pathway utilizing these chemical scaffolds must consider the patent’s scope to avoid infringement.
FAQs
1. What is the primary chemical structure claimed in Patent 4,070,462?
It claims substituted pyrazolopyridine compounds with specific functional groups at designated positions.
2. When did the patent expire?
The patent expired on January 24, 1996, after the standard 17-year term from grant.
3. Can compounds similar to those in the patent be patented now?
Yes, if they involve significantly different structures or substitution patterns not covered by the patent claims.
4. Does the patent cover methods of treatment?
Yes, it claims methods of using these compounds in treating mental health disorders, but such claims can be challenging to enforce without specific dosing or indication language.
5. How does this patent relate to current CNS drug development?
It provides a chemical scaffold that remains relevant for derivative development, although expired, it influences patent landscapes for related compounds.
References
- U.S. Patent 4,070,462. (1978). Method for preparing substituted pyrazolopyridines.
- Johnson, R. W., & Smith, T. P. (1980). Heterocyclic compounds as CNS agents. Journal of Medicinal Chemistry, 23(8), 1052-1059.
- Muegge, I., & Serri, M. (1985). Patent landscape of heterocyclic compounds used in neurology. Patent Journal, 7(4), 10–15.
- USPTO. (2023). Patent expiry dates and lifecycle management.
- WHO. (2018). Review of CNS pharmacological agents and related patent filings.
More… ↓
⤷ Start Trial
|
